Advanced Cell Technology's Dr. Robert Lanza Testifies Before US Senate Subcommittee
Complete the form below to unlock access to ALL audio articles.
Advanced Cell Technology, Inc. has announced that Robert Lanza, M.D., Advanced Cell Technology's Vice President of Medical and Stem Cell Development, testified before the Senate Labor, Health & Human Services and Education Appropriations Subcommittee.
Dr. Lanza's testimony focused on support for wider availability of human embryonic stem cells for basic medical research.
Dr. Lanza is the principle author of a paper published online (ahead of print) on August 23 in the journal Nature, which described a technique for developing human embryonic stem cells with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD).
"Our hope is that the new method we described in Nature can be used to increase the number of cell lines that qualify for federal funding within the framework of existing U.S. laws and regulations," Dr. Lanza said.
William Caldwell, Advanced Cell Technology's Chief Executive Officer commented, "We believe our technology offers a significant forward step in the field of regenerative medicine and adds to the array of available technologies."
"Since Dr. Lanza testified here last year, we have progressed from applying the single-cell derivation technique from the mouse to the human."
"In that year alone, a million people died from diseases that could that could potentially be treated-and possibly cured-using future stem cell therapies. We urge wider availability of cell lines for medical research."
